Expression Of ETV4 And The Relationship Between Serum HER2 DNA And Clinical Features Of Breast Cancer

Objective: Previous studies have confirmed that overexpression ofETV4could induce malignant transformation of normal cells and promoteinvasion and metastasis of cancer cells. Thus, the present study intends toinvestigate the expression of ETV4in breast cancer and its relationship withclinical features and angiogenesis.Methods:97tissue specimens were collected from breast cancer andthe expression of ETV4was detected by immunohistochemistry.Microvascular endothelial cells were marked by CD34, and microvesseldensity (MVD) was calculated by Weidner’s method. The statisticalsoftware was used to analyze the relationship between ETV4and clinicalfeatures in breast cancer, and the relationship with MVD as well as existingpathological indicators(ER, PR, HER2and Ki-67).Results: ETV4was detected predominantly in the nucleus of the breastcancer cells, but not in the normal tissue surrounding breast cancer. Theexpression of ETV4had statistical difference in different tumor size andlymph node metastasis or not (P<0.05), and the significant differences existed in different pathological grades (P<0.01) and TNM stages (P<0.05)too. The MVD of breast cancer with ETV4positive expression (47.6±15.7)was obviously higher than that with ETV4negative expression (34.6±10.9)(P<0.01). There was significantly positive correlation between ETV4expression and MVD(r=0.247, P<0.01). Expression of ETV4was alsopositively correlated with HER2(r=0.241) and Ki-67(r=0.253). Specifically,there were significant differences about ETV4expression among differentexpression levels of HER2(P<0.05) and Ki-67(P<0.05), respectively.However, the similar results were not observed in different expressionlevels of PR and ER (P>0.05).Conclusion: The expression of ETV4had significant association withtumor size, lymph node metastasis, TNM stage, pathological grade andangiogenesis in breast cancer. And the role of ETV4worth to be furtherstudied in the choice of treatment program and the development of breastcancer. Objective: To establish a rapid method for detecting serum HER2DNA, and explore its diagnostic value and clinical significance amongbreast cancer.Methods: Serum specimens were collected from92breast cancerpatients,37benign breast disease patients and53healthy women. Based ongene recombination techniques, the pMD18-T-HER2plasmid wasconstructed successfully as the standard product for detecting the serumHER2DNA by real-time fluorescent quantitative polymerase chain reaction(FQ-PCR). The statistical software was utilized to analyze the relationshipbetween serum HER2DNA and clinical features in breast cancer as well asthe diagnostic value of serum HER2DNA.Results: The serum HER2DNA level of the breast cancer was3088.2(1681.4,5592.2) copies/μl, which was significantly higher than thatof benign breast disease (P<0.05) and healthy controls (P<0.05). And theserum HER2DNA level related closely with tumor size, lymph nodemetastasis, pathological grade and TNM stage, which had statistical difference with different levels of clinical features above (P<0.05). ROCcurve showed the diagnostic value of serum HER2DNA for breast cancerwith the sensitivity and specificity of72.6%and73.1%respectively at acut-off of1675.5copies/μl.Conclusion: Elevated serum HER2DNA levels were observed inbreast cancer patients, which were closely associated with clinical featuresamong breast cancer. Present results suggested that it could possesspotential diagnostic value for the laboratorial diagnosis of breast cancer.